CAC
CRSP icon

Certified Advisory Corp’s CRISPR Therapeutics CRSP Stock Holding History

Certified Advisory Corp’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-58
Closed -$2K – 760
2020
Q1 		$2K Hold
58
– – ﹤0.01% 687
2019
Q4 		$4K Buy
+58
New +$3.17K ﹤0.01% 673

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Certified Advisory Corp's CRSP Position: Q2 2020 in Review

Certified Advisory Corp sold out of CRISPR Therapeutics (CRSP) in Q2 2020, closing a stake of 58 shares — an estimated $2K sold.

Certified Advisory Corp first reported a position in CRSP in Q4 2019 and held it in 2 quarters. The position peaked at $4K in Q4 2019. 276 funds tracked by Wall St. Rank hold CRSP as of Q2 2020.

  • Certified Advisory Corp reported no remaining CRISPR Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Certified Advisory Corp sold 58 CRISPR Therapeutics shares in Q2 2020, an estimated $2K.
  • Certified Advisory Corp first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 2 quarters.
  • Certified Advisory Corp's CRISPR Therapeutics position peaked at $4K in Q4 2019.
  • 276 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2020.

Based on Certified Advisory Corp's 13F filing for Q2 2020, filed 27 Jul 2020.